Tidutamab

Tax included
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).
MedChemExpress 
HY-P99562

Data sheet

Size
Multiple sizes
Reactivity
CD3
Application
Cancer-programmed cell death
CAS
2148354-90-7